Suvretta Capital Management
Latest statistics and disclosures from Suvretta Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMZN, MSFT, UNH, ADBE, OTIS, and represent 25.54% of Suvretta Capital Management's stock portfolio.
- Added to shares of these 10 stocks: MSFT (+$291M), MNST (+$110M), HLT (+$93M), MAR (+$82M), DECK (+$79M), DHR (+$72M), ADI (+$60M), RIVN (+$53M), RARE (+$41M), MRTX (+$31M).
- Started 20 new stock positions in RARE, GRAB, ROIV, ABCL, MAR, MSFT, TRDA, ALLO, RIVN, OHAAU. DHR, HLT, PHVS, SRNE, ETSY, MNST, DECK, MGTX, AMAM, MQ.
- Reduced shares in these 10 stocks: MA (-$214M), TWLO (-$165M), ADBE (-$138M), PLAN (-$132M), UNH (-$130M), ROST (-$122M), MDT (-$114M), KBR (-$109M), PTON (-$102M), CPRT (-$86M).
- Sold out of its positions in ADAG, Alight, PLAN, ACHR, BCAB, DCPH, EVLV, Fs Development Corp Ii, FSRX, FHTX.
- Suvretta Capital Management was a net seller of stock by $-852M.
- Suvretta Capital Management has $5.2B in assets under management (AUM), dropping by -12.98%.
- Central Index Key (CIK): 0001569064
Tip: Access up to 7 years of quarterly data
Positions held by Suvretta Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Suvretta Capital Management
Companies in the Suvretta Capital Management portfolio as of the December 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amazon (AMZN) | 7.0 | $360M | +8% | 108k | 3334.34 | |
| Microsoft Corporation (MSFT) | 5.6 | $291M | NEW | 865k | 336.32 | |
| UnitedHealth (UNH) | 4.4 | $229M | -36% | 457k | 502.14 | |
| Adobe Systems Incorporated (ADBE) | 4.3 | $222M | -38% | 392k | 567.06 | |
| Otis Worldwide Corp (OTIS) | 4.2 | $216M | -7% | 2.5M | 87.07 | |
| Union Pacific Corporation (UNP) | 3.9 | $204M | 808k | 251.93 | ||
| Tapestry (TPR) | 3.6 | $185M | -15% | 4.5M | 40.60 | |
| Thermo Fisher Scientific (TMO) | 3.5 | $181M | -16% | 271k | 667.24 | |
| Gfl Environmental Sub Vtg Shs (GFL) | 3.4 | $175M | 4.6M | 37.85 | ||
| Lauder Estee Cos Cl A (EL) | 3.2 | $166M | -12% | 449k | 370.20 | |
| AmerisourceBergen (ABC) | 3.2 | $165M | 1.2M | 132.89 | ||
| Iqvia Holdings (IQV) | 3.1 | $158M | -20% | 560k | 282.14 | |
| Analog Devices (ADI) | 2.8 | $144M | +71% | 819k | 175.77 | |
| Rh (RH) | 2.6 | $134M | -25% | 250k | 535.94 | |
| Quanta Services (PWR) | 2.6 | $133M | -16% | 1.2M | 114.66 | |
| Monster Beverage Corp (MNST) | 2.1 | $110M | NEW | 1.1M | 96.04 | |
| Carvana Cl A (CVNA) | 1.9 | $99M | -10% | 428k | 231.79 | |
| Hilton Worldwide Holdings (HLT) | 1.8 | $93M | NEW | 599k | 155.99 | |
| Opendoor Technologies (OPEN) | 1.7 | $90M | -34% | 6.2M | 14.61 | |
| Mastercard Incorporated Cl A (MA) | 1.7 | $90M | -70% | 250k | 359.32 | |
| Cano Health Com Cl A (CANO) | 1.7 | $88M | +17% | 9.9M | 8.91 | |
| Alight Com Cl A (ALIT) | 1.6 | $84M | -6% | 7.8M | 10.81 | |
| Marriott Intl Cl A (MAR) | 1.6 | $82M | NEW | 494k | 165.24 | |
| Deckers Outdoor Corporation (DECK) | 1.5 | $79M | NEW | 216k | 366.31 | |
| Royalty Pharma Shs Class A (RPRX) | 1.5 | $78M | +28% | 2.0M | 39.85 | |
| Danaher Corporation (DHR) | 1.4 | $72M | NEW | 220k | 329.01 | |
| Block Cl A (SQ) | 1.3 | $69M | +41% | 430k | 161.51 | |
| Intra Cellular Therapies (ITCI) | 1.3 | $66M | 1.3M | 52.34 | ||
| Te Connectivity SHS (TEL) | 1.2 | $62M | -36% | 383k | 161.34 | |
| Natera (NTRA) | 1.2 | $59M | -14% | 636k | 93.39 | |
| Mirati Therapeutics (MRTX) | 1.1 | $59M | +110% | 403k | 146.69 | |
| Rivian Automotive Com Cl A (RIVN) | 1.0 | $53M | NEW | 508k | 103.69 | |
| Kura Oncology (KURA) | 1.0 | $50M | +45% | 3.6M | 14.00 | |
| Copart (CPRT) | 0.9 | $46M | -65% | 305k | 151.62 | |
| Fulcrum Therapeutics (FULC) | 0.8 | $42M | +22% | 2.4M | 17.69 | |
| Ultragenyx Pharmaceutical (RARE) | 0.8 | $41M | NEW | 485k | 84.09 | |
| Agios Pharmaceuticals (AGIO) | 0.7 | $39M | -10% | 1.2M | 32.87 | |
| Sutro Biopharma (STRO) | 0.7 | $36M | +9% | 2.4M | 14.88 | |
| Warby Parker Cl A Com (WRBY) | 0.7 | $34M | -26% | 733k | 46.56 | |
| KBR (KBR) | 0.6 | $33M | -77% | 686k | 47.62 | |
| Marinus Pharmaceuticals Com New (MRNS) | 0.6 | $31M | +20% | 2.6M | 11.88 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.6 | $31M | +47% | 2.5M | 12.24 | |
| Insmed Com Par $.01 (INSM) | 0.6 | $30M | +8% | 1.1M | 27.24 | |
| Etsy (ETSY) | 0.5 | $27M | NEW | 122k | 218.94 | |
| Marqeta Class A Com (MQ) | 0.5 | $25M | NEW | 1.5M | 17.17 | |
| Kezar Life Sciences (KZR) | 0.5 | $24M | 1.4M | 16.72 | ||
| Kalvista Pharmaceuticals (KALV) | 0.4 | $23M | +13% | 1.7M | 13.23 | |
| Arena Pharmaceuticals Com New | 0.4 | $23M | -51% | 246k | 92.94 | |
| Heron Therapeutics (HRTX) | 0.4 | $23M | +66% | 2.5M | 9.13 | |
| Xenon Pharmaceuticals (XENE) | 0.4 | $22M | -40% | 692k | 31.24 | |
| Chinook Therapeutics (KDNY) | 0.4 | $20M | +19% | 1.2M | 16.31 | |
| Coherus Biosciences (CHRS) | 0.4 | $20M | +149% | 1.2M | 15.96 | |
| Chimerix (CMRX) | 0.3 | $18M | +45% | 2.8M | 6.43 | |
| Inflarx Nv (IFRX) | 0.3 | $16M | 3.3M | 4.76 | ||
| Point Biopharma Global (PNT) | 0.3 | $15M | +20% | 2.7M | 5.60 | |
| Mereo Biopharma Group Ads (MREO) | 0.3 | $15M | 9.1M | 1.60 | ||
| Grab Holdings Class A Ord (GRAB) | 0.3 | $14M | NEW | 2.0M | 7.13 | |
| Aeglea Biotherapeutics (AGLE) | 0.2 | $12M | +19% | 2.6M | 4.75 | |
| Pharvaris N V (PHVS) | 0.2 | $12M | NEW | 828k | 14.39 | |
| Solid Biosciences (SLDB) | 0.2 | $11M | +5% | 6.3M | 1.75 | |
| Bolt Biotherapeutics (BOLT) | 0.2 | $11M | +68% | 2.2M | 4.90 | |
| Dice Therapeutics (DICE) | 0.2 | $10M | 410k | 25.31 | ||
| Ambrx Biopharma Sponsored Ads (AMAM) | 0.2 | $9.6M | NEW | 1.1M | 9.03 | |
| Terns Pharmaceuticals (TERN) | 0.2 | $8.8M | +10% | 1.2M | 7.07 | |
| Molecular Partners Ads (MOLN) | 0.1 | $7.7M | 400k | 19.18 | ||
| Sio Gene Therapies Common (SIOX) | 0.1 | $7.6M | +7% | 5.9M | 1.29 | |
| Inozyme Pharma (INZY) | 0.1 | $6.9M | +2% | 1.0M | 6.82 | |
| Gemini Therapeutics (GMTX) | 0.1 | $6.9M | +10% | 2.4M | 2.91 | |
| Roivant Sciences SHS (ROIV) | 0.1 | $6.9M | NEW | 682k | 10.08 | |
| Oric Pharmaceuticals (ORIC) | 0.1 | $6.5M | +195% | 441k | 14.70 | |
| Milestone Pharmaceuticals (MIST) | 0.1 | $5.6M | 851k | 6.55 | ||
| Otonomy (OTIC) | 0.1 | $5.6M | +12% | 2.7M | 2.08 | |
| Abcellera Biologics Call Option (ABCL) | 0.1 | $5.3M | NEW | 367k | 14.30 | |
| Research Alliance Corp Ii Com Cl A (RACB) | 0.1 | $4.9M | 500k | 9.77 | ||
| Allogene Therapeutics (ALLO) | 0.1 | $4.0M | NEW | 265k | 14.92 | |
| Nuvalent Inc-a (NUVL) | 0.1 | $3.8M | 200k | 19.04 | ||
| Immuneering Corp Class A Com (IMRX) | 0.1 | $3.2M | 200k | 16.17 | ||
| Omega Alpha Spac Cl A (OMEG) | 0.1 | $2.9M | 300k | 9.77 | ||
| European Biotech Acqutn Corp Class A Ord Shs (EBAC) | 0.1 | $2.9M | 300k | 9.69 | ||
| Benitec Biopharma (BNTC) | 0.0 | $2.0M | 769k | 2.62 | ||
| Opy Acquisition Corp I Unit 09/22/2026 (OHAAU) | 0.0 | $2.0M | NEW | 200k | 10.00 | |
| Turmeric Acquisition Corp Cl A (TMPM) | 0.0 | $2.0M | 200k | 9.82 | ||
| Bcls Acquisition Corp Com Cl A (BLSA) | 0.0 | $2.0M | 200k | 9.80 | ||
| Entrada Therapeutics (TRDA) | 0.0 | $1.8M | NEW | 106k | 17.12 | |
| Cano Health *w Exp 06/03/202 (CANO.WS) | 0.0 | $1.6M | 675k | 2.39 | ||
| Decibel Therapeutics (DBTX) | 0.0 | $1.2M | 264k | 4.65 | ||
| Eucrates Biomedical Acqu Cor SHS (EUCR) | 0.0 | $976k | 100k | 9.76 | ||
| Frazier Lifesciences Acqu Cl A Shs (FLAC) | 0.0 | $853k | 88k | 9.75 | ||
| Meiragtx Holdings (MGTX) | 0.0 | $821k | NEW | 35k | 23.73 | |
| Sorrento Therapeutics Com New (SRNE) | 0.0 | $492k | NEW | 106k | 4.65 | |
| Finserv Acquisition Corp Ii *w Exp 02/17/202 (FSRXW) | 0.0 | $169k | 273k | 0.62 | ||
| European Biotech Acqutn Corp *w Exp 03/06/202 (EBACW) | 0.0 | $60k | 100k | 0.60 | ||
| Turmeric Acquisition Corp *w Exp 10/08/202 (TMPMW) | 0.0 | $45k | 67k | 0.68 | ||
| Eucrates Biomedical Acqu Cor *w Exp 10/23/202 (EUCRW) | 0.0 | $19k | 33k | 0.57 | ||
| Frazier Lifesciences Acqu *w Exp 11/30/202 (FLACW) | 0.0 | $17k | 29k | 0.58 |
Past Filings by Suvretta Capital Management
SEC 13F filings are viewable for Suvretta Capital Management going back to 2013
- Suvretta Capital Management 2021 Q4 filed Feb. 14, 2022
- Suvretta Capital Management 2021 Q3 restated filed Nov. 16, 2021
- Suvretta Capital Management 2021 Q3 filed Nov. 15, 2021
- Suvretta Capital Management 2021 Q3 amended filed Nov. 15, 2021
- Suvretta Capital Management 2021 Q2 filed Aug. 16, 2021
- Suvretta Capital Management 2021 Q1 filed May 17, 2021
- Suvretta Capital Management 2020 Q4 filed Feb. 16, 2021
- Suvretta Capital Management 2020 Q3 filed Nov. 16, 2020
- Suvretta Capital Management 2020 Q2 filed Aug. 14, 2020
- Suvretta Capital Management 2020 Q1 filed May 15, 2020
- Suvretta Capital Management 2019 Q4 filed Feb. 14, 2020
- Suvretta Capital Management 2019 Q3 filed Nov. 14, 2019
- Suvretta Capital Management 2019 Q2 filed Aug. 14, 2019
- Suvretta Capital Management 2019 Q1 filed May 15, 2019
- Suvretta Capital Management 2018 Q4 filed Feb. 14, 2019
- Suvretta Capital Management 2018 Q3 filed Nov. 14, 2018